1. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma
- Author
-
Hyunsoo Lee, Ji-Soo Oh, Jun Ho Lee, Jie-Young Song, Kyung-Eun Noh, Dae-Seog Lim, Nam-Chul Jung, Han Geuk Seo, Yu Wang, So-Yeon Choi, and Ji-Hee Nam
- Subjects
chimeric antigen receptor-T cell ,Mice, SCID ,Immunotherapy, Adoptive ,Cell therapy ,Mice ,Mice, Inbred NOD ,Transforming Growth Factor beta ,hemic and lymphatic diseases ,Biology (General) ,B-cell lymphoma ,Cytotoxicity ,Receptor ,Spectroscopy ,Cells, Cultured ,Receptors, Chimeric Antigen ,biology ,Chemistry ,chimeric switch receptor ,General Medicine ,Computer Science Applications ,Treatment Outcome ,Female ,Signal Transduction ,TGF-β ,Lymphoma, B-Cell ,QH301-705.5 ,Antigens, CD19 ,chemical and pharmacologic phenomena ,Catalysis ,CD19 ,Article ,Inorganic Chemistry ,In vivo ,medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,QD1-999 ,Interleukin-7 ,Organic Chemistry ,medicine.disease ,Xenograft Model Antitumor Assays ,Chimeric antigen receptor ,In vitro ,B cell lymphoma ,Cancer research ,biology.protein ,Neoplasm Recurrence, Local ,K562 Cells ,Single-Chain Antibodies - Abstract
Chimeric antigen receptor (CAR)-T cells are effective in the treatment of hematologic malignancies but have shown limited efficacy against solid tumors. Here, we demonstrated an approach to inhibit recurrence of B cell lymphoma by co-expressing both a human anti-CD19-specific single-chain variable fragment (scFv) CAR (CD19 CAR) and a TGF-β/IL-7 chimeric switch receptor (tTRII-I7R) in T cells (CD19 CAR-tTRII-I7R-T cells). The tTRII-I7R was designed to convert immunosuppressive TGF-β signaling into immune-activating IL-7 signaling. The effect of TGF-β on CD19 CAR-tTRII-I7R-T cells was assessed by western blotting. Target-specific killing by CD19 CAR-tTRII-I7R-T cells was evaluated by Eu-TDA assay. Daudi tumor-bearing NSG (NOD/SCID/IL2Rγ-/-) mice were treated with CD19 CAR-tTRII-I7R-T cells to analyze the in vivo anti-tumor effect. In vitro, CD19 CAR-tTRII-I7R-T cells had a lower level of phosphorylated SMAD2 and a higher level of target-specific cytotoxicity than controls in the presence of rhTGF-β1. In the animal model, the overall survival and recurrence-free survival of mice that received CD19 CAR-tTRII-I7R-T cells were significantly longer than in control mice. These findings strongly suggest that CD19 CAR-tTRII-I7R-T cell therapy provides a new strategy for long-lasting, TGF-β-resistant anti-tumor effects against B cell lymphoma, which may lead ultimately to increased clinical efficacy.
- Published
- 2021